Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Eur J Pharm Sci. 2020 Jul 23;153:105488. doi: 10.1016/j.ejps.2020.105488

Figure 9. Roles of CYPs in the formation of M4, M14, M15, M20 and M30.

Figure 9.

TCP (10.0 µM, CYP2B6 inhibitor), KCZ (2.0 μM, CYP3A4 inhibitor), NF, (6.0 µM, CYP1A2 inhibitor); NT, (10.0 µM, CYP2C19 inhibitor); QT, (30.0 µM, CYP2C8 inhibitor), and Qui (2.0 μM, CYP2D6 inhibitor) were used in the inhibitory tests in HLM. The incubation conditions of ATX in HLM were detailed in experimental procedures. All samples were analyzed by UHPLC-Q Exactive MS. (A) Effects of TCP on the formations of M4 and M30 in HLM. The relative abundance of M4 and M30 from the incubation with HLM in the absence of TCP was set as 100%. (B) Effects of KCZ on the formations of M4 in HLM. The relative abundance of M4 from the incubation in HLM without KCZ was set as 100%. (C-E) Effects of QT, NT, and on the formations of M30 in HLM. The relative abundance of M30 from the incubation in HLM without QT, NT and Qui was set as 100%. (F) Effects of Qui on the formations of M14, M15 and M20 in HLM. The relative abundance of M14, M15 and M20 from the incubation in HLM without Qui was set as 100%. All data are expressed as mean ± SEM (n = 3). P*<0.05, **P<0.01. KCZ, ketoconazole; Qui, quinidine; TCP, ticlopidine; NF, alpha-naphthoflavone; NT, nootkatone; QT, quercetin.